Compare Amgen, Inc. (AMGN) vs MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs MicroSectors FANG and Innovation 3X Leveraged ETN — how do they compare? Amgen, Inc. trades at $357.09 (market cap $196.12B), while MicroSectors FANG and Innovation 3X Leveraged ETN trades at $28.45. The key difference: Amgen, Inc. pays a 2.77% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none. Which is the better fit depends on your goals.
| AMGN | FNGU | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $388.16 | $36.15 |
52-Week Low | $271.18 | $13.73 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
FNGU trades at $28.64, up 0.77% on the day, with technical indicators showing a bullish trend from moving averages but caution from oscillators like the 6-day RSI at 95.66. Recent news highlights extreme volatility, with a 16% single-session drop reported on June 5, 2026, underscoring the leveraged ETN's high-risk nature. The asset lacks traditional fundamental metrics like P/E or revenue data, as it is an exchange-traded note tracking the FANG+ Index with 3x leverage.
The outlook for FNGU is highly speculative, driven by momentum in tech stocks but fraught with decay risks from daily rebalancing. Opportunities exist for short-term traders betting on Nasdaq-100 rallies, while risks include rapid capital erosion during market downturns, as evidenced by recent losses. Investors must understand the product's structure to avoid unintended losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →
